Market Cap 138.19M
Revenue (ttm) 0.00
Net Income (ttm) -30.05M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 199,450
Avg Vol 508,106
Day's Range N/A - N/A
Shares Out 63.68M
Stochastic %K 54%
Beta -0.05
Analysts Strong Sell
Price Target $7.87

Company Profile

TuHURA Biosciences, Inc., a clinical stage immuno-oncology company, that develops novel technologies for the treatment of cancer immunotherapies. The company's lead product candidate includes IFx2.0, an innate immune agonist designed to overcome primary resistance to checkpoint inhibitors. It is also preparing to initiate a single randomized placebo-controlled which is in Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda; and Delta receptor technology to dev...

Industry: Biotechnology
Sector: Healthcare
Phone: 813 875 6600
Address:
10500 University Center Drive, Suite 110, Tampa, United States
TuHURA_IR
TuHURA_IR Aug. 3 at 5:12 PM
$HURA One of the biggest challenges in immuno-oncology is that checkpoint inhibitors don't benefit every patient. Understanding why helps explain the rationale behind IFx-2.0. These therapies help when the immune system has already recognized a tumor as foreign but has been held back from acting on it. When the immune system never identified the tumor in the first place, there is nothing for the drug to unblock. IFx-2.0 is designed to address that gap. Our platform is intended to make the tumor appear foreign, activating both the innate and adaptive immune responses before checkpoint inhibition does its job. https://youtu.be/D_fyKz0l8ms
0 · Reply
TuHURA_IR
TuHURA_IR Jul. 31 at 1:52 PM
$HURA Why focus on patients with the NPM1 mutation? Because modern leukemia research increasingly defines treatment strategies around the specific mutations driving the disease. In acute myeloid leukemia, the NPM1 mutation is one of the most common, and it is also associated with elevated VISTA expression on the leukemic blast, the mechanism TBS-2025 is designed to address. Our TBS-2025 Phase 1b/2 is an open-label study designed to evaluate multiple dose levels in patients with relapsed or refractory NPM1-mutated AML who show low or short-duration response to menin inhibitor therapies. In this clip, Dr. James Bianco walks through the study design and the rationale for selecting this patient population. https://youtu.be/wQghDriGmXc
0 · Reply
TuHURA_IR
TuHURA_IR Jul. 29 at 1:56 PM
$HURA Why has TuHURA invested in targeting VISTA? The answer starts with how certain cancers evade the immune system. The immune system relies on checkpoints, molecular signals that tell T cells when to stand down so they don't damage healthy tissue. Many cancers survive by exploiting those same signals. VISTA is a checkpoint expressed on resting T cells and highly expressed on myeloid cells. In acute myeloid leukemia, the NPM1 mutation drives VISTA expression on leukemic blasts, reported to be the primary mechanism by which AML escapes recognition by the immune system. That biology is the foundation of our TBS-2025 program. We are the first company to advance a VISTA-inhibiting antibody for investigation in hematologic cancers, and we recently filed an IND with the FDA to begin a Phase 1b/2 study. https://youtu.be/4ObTdHvp5CM
0 · Reply
TuHURA_IR
TuHURA_IR Jul. 27 at 1:57 PM
$HURA Our President and CEO, Dr. James Bianco, will present at the Canaccord Genuity 46th Annual Growth Conference on Wednesday, August 12 at 12:30pm ET in Boston. The conference is a key institutional platform for growth-stage companies, and the presentation provides an opportunity to share our pipeline, development strategy, and near-term milestones with a broader investor audience. For registration and the live webcast, please visit the link in our press release. An archived webcast will be available on our Investor Relations page after the event. Full press release: https://ir.tuhurabio.com/news-events/press-releases/detail/47/tuhura-biosciences-to-present-at-canaccord-genuitys-46th-annual-growth-conference
0 · Reply
letsgoobulls
letsgoobulls Jul. 24 at 7:22 PM
$HURA is this still going $10 to $15 by end of year?
0 · Reply
StocksandRealEstate
StocksandRealEstate Jul. 24 at 2:47 PM
$HURA When it moves, I believe it will happen fast.
0 · Reply
TuHURA_IR
TuHURA_IR Jul. 24 at 1:11 PM
$HURA Our President and CEO, Dr. James Bianco, sat down for an AMA for a deep dive into our clinical programs, development strategy, and the milestones ahead. The conversation covers our TBS-2025 VISTA-inhibiting antibody program in acute myeloid leukemia (AML), our ongoing Phase 3 trial of IFx-2.0 in first-line Merkel cell carcinoma, our antibody-drug conjugate platform, and our approach to capital allocation and portfolio management. The session reinforces our positioning as a multi-asset immuno-oncology company advancing three programs in parallel, and gives investors additional visibility into the execution ahead. Watch the full session here: https://youtu.be/J2ln1myzy6c
0 · Reply
Emergency123
Emergency123 Jul. 23 at 5:12 PM
$HURA Lets GO ADTX taking off guys, get some eyes on it!
0 · Reply
stackerz
stackerz Jul. 23 at 4:00 PM
$HURA I like where its going for such a small company. Did you peruse its 2025 prospectus, when it merged with Kineta? Volume is low these days, but you’re feeling good if you bought heavier early in 2026. Just need a little spark.
0 · Reply
PastaSlobCFA
PastaSlobCFA Jul. 23 at 12:42 PM
$HURA been holding $2.19 for a while now. $7.00 by the end of Aug
0 · Reply
Latest News on HURA
TuHURA Biosciences Proxy statement: Proxy filing

Jul 9, 2026, 8:00 AM EDT - 26 days ago

TuHURA Biosciences Proxy statement: Proxy filing


TuHURA Biosciences Proxy statement: Proxy filing

Jul 9, 2026, 8:00 AM EDT - 26 days ago

TuHURA Biosciences Proxy statement: Proxy filing


TuHURA Biosciences Proxy statement: Proxy filing

Jun 26, 2026, 8:00 AM EDT - 5 weeks ago

TuHURA Biosciences Proxy statement: Proxy filing


TuHURA Biosciences Earnings release: Q1 2026

May 15, 2026, 7:00 AM EDT - 2 months ago

TuHURA Biosciences Earnings release: Q1 2026


TuHURA Biosciences Quarterly report: Q1 2026

May 15, 2026, 7:00 AM EDT - 2 months ago

TuHURA Biosciences Quarterly report: Q1 2026


TuHURA Biosciences Slides: Corporate presentation

May 15, 2026, 7:00 AM EDT - 2 months ago

TuHURA Biosciences Slides: Corporate presentation


TuHURA Biosciences initiated with an Outperform at Citizens

2026-04-27T08:45:56.000Z - 3 months ago

TuHURA Biosciences initiated with an Outperform at Citizens


TuHURA Biosciences initiated with a Buy at Rodman & Renshaw

2026-04-15T12:20:48.000Z - 3 months ago

TuHURA Biosciences initiated with a Buy at Rodman & Renshaw


TuHURA Biosciences Earnings release: Q4 2025

Mar 31, 2026, 7:00 AM EDT - 4 months ago

TuHURA Biosciences Earnings release: Q4 2025


TuHURA Biosciences Annual report: Q4 2025

Mar 31, 2026, 7:00 AM EDT - 4 months ago

TuHURA Biosciences Annual report: Q4 2025


TuHURA Biosciences announces release of Kintara’s CVR

2025-12-15T13:06:01.000Z - 8 months ago

TuHURA Biosciences announces release of Kintara’s CVR


TuHURA Biosciences provides updates across portfolio

2025-12-11T12:35:31.000Z - 8 months ago

TuHURA Biosciences provides updates across portfolio


TuHURA Biosciences announces $15.6M registered direct offering

2025-12-09T14:55:32.000Z - 8 months ago

TuHURA Biosciences announces $15.6M registered direct offering


TuHURA Biosciences price target lowered to $8 from $15 at Maxim

2025-11-14T17:20:32.000Z - 9 months ago

TuHURA Biosciences price target lowered to $8 from $15 at Maxim


TuHURA Biosciences Earnings release: Q3 2025

Nov 14, 2025, 7:00 AM EST - 9 months ago

TuHURA Biosciences Earnings release: Q3 2025


TuHURA Biosciences Quarterly report: Q3 2025

Nov 14, 2025, 7:00 AM EST - 9 months ago

TuHURA Biosciences Quarterly report: Q3 2025


TuHURA Biosciences files $250M mixed securities shelf

2025-11-03T22:35:14.000Z - 9 months ago

TuHURA Biosciences files $250M mixed securities shelf


TuHURA Biosciences Registration statement: Registration filing

Nov 3, 2025, 7:00 AM EST - 9 months ago

TuHURA Biosciences Registration statement: Registration filing


TuHURA Biosciences Registration statement: Registration filing

Sep 18, 2025, 8:00 AM EDT - 11 months ago

TuHURA Biosciences Registration statement: Registration filing


TuHURA Biosciences Earnings release: Q2 2025

Aug 14, 2025, 7:00 AM EDT - 1 year ago

TuHURA Biosciences Earnings release: Q2 2025


TuHURA Biosciences Quarterly report: Q2 2025

Aug 14, 2025, 7:00 AM EDT - 1 year ago

TuHURA Biosciences Quarterly report: Q2 2025


TuHURA Biosciences included in Russell 3000 and 2000 Indexes

2025-07-01T12:55:33.000Z - 1 year ago

TuHURA Biosciences included in Russell 3000 and 2000 Indexes


TuHURA Biosciences Completes Acquisition of Kineta

Jun 30, 2025, 8:50 AM EDT - 1 year ago

TuHURA Biosciences Completes Acquisition of Kineta


TuHURA Biosciences initiated with a Buy at Brookline

2025-06-23T17:48:27.000Z - 1 year ago

TuHURA Biosciences initiated with a Buy at Brookline


TuHURA Biosciences Earnings release: Q1 2025

May 15, 2025, 7:00 AM EDT - 1 year ago

TuHURA Biosciences Earnings release: Q1 2025


TuHURA Biosciences Quarterly report: Q1 2025

May 15, 2025, 7:00 AM EDT - 1 year ago

TuHURA Biosciences Quarterly report: Q1 2025


TuHURA Biosciences Annual report: Q4 2024

Mar 31, 2025, 7:00 AM EDT - 1 year ago

TuHURA Biosciences Annual report: Q4 2024


TuHURA Biosciences Earnings release: Q4 2024

Mar 31, 2025, 7:00 AM EDT - 1 year ago

TuHURA Biosciences Earnings release: Q4 2024


TuHURA Biosciences, Inc Appoints Craig L. Tendler M.D.

Mar 11, 2025, 8:05 AM EDT - 1 year ago

TuHURA Biosciences, Inc Appoints Craig L. Tendler M.D.


TuHURA Biosciences Quarterly report: Q3 2024

Nov 14, 2024, 7:00 AM EST - 1 year ago

TuHURA Biosciences Quarterly report: Q3 2024


TuHURA_IR
TuHURA_IR Aug. 3 at 5:12 PM
$HURA One of the biggest challenges in immuno-oncology is that checkpoint inhibitors don't benefit every patient. Understanding why helps explain the rationale behind IFx-2.0. These therapies help when the immune system has already recognized a tumor as foreign but has been held back from acting on it. When the immune system never identified the tumor in the first place, there is nothing for the drug to unblock. IFx-2.0 is designed to address that gap. Our platform is intended to make the tumor appear foreign, activating both the innate and adaptive immune responses before checkpoint inhibition does its job. https://youtu.be/D_fyKz0l8ms
0 · Reply
TuHURA_IR
TuHURA_IR Jul. 31 at 1:52 PM
$HURA Why focus on patients with the NPM1 mutation? Because modern leukemia research increasingly defines treatment strategies around the specific mutations driving the disease. In acute myeloid leukemia, the NPM1 mutation is one of the most common, and it is also associated with elevated VISTA expression on the leukemic blast, the mechanism TBS-2025 is designed to address. Our TBS-2025 Phase 1b/2 is an open-label study designed to evaluate multiple dose levels in patients with relapsed or refractory NPM1-mutated AML who show low or short-duration response to menin inhibitor therapies. In this clip, Dr. James Bianco walks through the study design and the rationale for selecting this patient population. https://youtu.be/wQghDriGmXc
0 · Reply
TuHURA_IR
TuHURA_IR Jul. 29 at 1:56 PM
$HURA Why has TuHURA invested in targeting VISTA? The answer starts with how certain cancers evade the immune system. The immune system relies on checkpoints, molecular signals that tell T cells when to stand down so they don't damage healthy tissue. Many cancers survive by exploiting those same signals. VISTA is a checkpoint expressed on resting T cells and highly expressed on myeloid cells. In acute myeloid leukemia, the NPM1 mutation drives VISTA expression on leukemic blasts, reported to be the primary mechanism by which AML escapes recognition by the immune system. That biology is the foundation of our TBS-2025 program. We are the first company to advance a VISTA-inhibiting antibody for investigation in hematologic cancers, and we recently filed an IND with the FDA to begin a Phase 1b/2 study. https://youtu.be/4ObTdHvp5CM
0 · Reply
TuHURA_IR
TuHURA_IR Jul. 27 at 1:57 PM
$HURA Our President and CEO, Dr. James Bianco, will present at the Canaccord Genuity 46th Annual Growth Conference on Wednesday, August 12 at 12:30pm ET in Boston. The conference is a key institutional platform for growth-stage companies, and the presentation provides an opportunity to share our pipeline, development strategy, and near-term milestones with a broader investor audience. For registration and the live webcast, please visit the link in our press release. An archived webcast will be available on our Investor Relations page after the event. Full press release: https://ir.tuhurabio.com/news-events/press-releases/detail/47/tuhura-biosciences-to-present-at-canaccord-genuitys-46th-annual-growth-conference
0 · Reply
letsgoobulls
letsgoobulls Jul. 24 at 7:22 PM
$HURA is this still going $10 to $15 by end of year?
0 · Reply
StocksandRealEstate
StocksandRealEstate Jul. 24 at 2:47 PM
$HURA When it moves, I believe it will happen fast.
0 · Reply
TuHURA_IR
TuHURA_IR Jul. 24 at 1:11 PM
$HURA Our President and CEO, Dr. James Bianco, sat down for an AMA for a deep dive into our clinical programs, development strategy, and the milestones ahead. The conversation covers our TBS-2025 VISTA-inhibiting antibody program in acute myeloid leukemia (AML), our ongoing Phase 3 trial of IFx-2.0 in first-line Merkel cell carcinoma, our antibody-drug conjugate platform, and our approach to capital allocation and portfolio management. The session reinforces our positioning as a multi-asset immuno-oncology company advancing three programs in parallel, and gives investors additional visibility into the execution ahead. Watch the full session here: https://youtu.be/J2ln1myzy6c
0 · Reply
Emergency123
Emergency123 Jul. 23 at 5:12 PM
$HURA Lets GO ADTX taking off guys, get some eyes on it!
0 · Reply
stackerz
stackerz Jul. 23 at 4:00 PM
$HURA I like where its going for such a small company. Did you peruse its 2025 prospectus, when it merged with Kineta? Volume is low these days, but you’re feeling good if you bought heavier early in 2026. Just need a little spark.
0 · Reply
PastaSlobCFA
PastaSlobCFA Jul. 23 at 12:42 PM
$HURA been holding $2.19 for a while now. $7.00 by the end of Aug
0 · Reply
2TrustHim
2TrustHim Jul. 13 at 6:59 PM
$HURA Is $2.60 Coming Back Before Close?
0 · Reply
BillionerOfKing
BillionerOfKing Jul. 9 at 9:43 PM
$HURA Current Stock Price: $2.35
0 · Reply
2TrustHim
2TrustHim Jul. 9 at 8:27 PM
$HURA Form ARS!!!
2 · Reply
hhhhfdf
hhhhfdf Jul. 9 at 5:58 PM
$HURA Any updates, about new orphan drug status?
0 · Reply
TuHURA_IR
TuHURA_IR Jul. 6 at 2:42 PM
$HURA Our planned Phase 1b/2 study of TBS-2025 in AML combines two phases of clinical development into a single integrated trial. Dr. Craig Tendler, CMO consultant overseeing the TBS-2025 development program and TuHURA Board member, described the design in the June 15 announcement: "The FDA provided valuable feedback and comprehensive guidance on trial design, which we incorporated into our proposed Phase 1b dose optimization trial. Our plan is to combine the Phase 1b with the Phase 2 study for a combination study design that is much more efficient and could potentially save 4-6 months in development time." We anticipate FDA written responses in July 2026 and, depending on those responses, are targeting initiation of the trial in the second half of 2026.
0 · Reply
Gotsomescrewsmissing
Gotsomescrewsmissing Jul. 4 at 1:21 PM
$PLUG $FLY $HURA worth watching Texas Stock Exchange to launch trading Monday https://share.google/LyvdsxhtkUclEjNQJ
0 · Reply
TuHURA_IR
TuHURA_IR Jul. 2 at 1:52 PM
$HURA In AML patients with NPM1 mutations, VISTA expression has been associated with low response rates of short duration following current therapies, including recently approved menin inhibitors. The June 15 IND filing for TBS-2025 is designed to study whether blocking VISTA can change those outcomes. As President and CEO Dr. James Bianco described in the announcement: "Currently, there are no approved or effective treatment options for these patient populations, representing a significant unmet medical need." We are targeting initiation of the Phase 1b/2 study in the second half of 2026, following FDA written responses anticipated in July 2026.
0 · Reply
TuHURA_IR
TuHURA_IR Jun. 30 at 8:48 PM
$HURA Our pipeline now extends from Merkel Cell Carcinoma into AML and other blood-related cancers, with TBS-2025 targeting VISTA-driven immune evasion alongside our ongoing IFx-2.0 program. On June 15, we filed an Investigational New Drug application with the FDA for TBS-2025, our VISTA-inhibiting antibody, in molecularly defined subsets of acute myeloid leukemia (AML) and other blood-related cancers. The IND covers patients with NPM1 mutations and, in the future, those with FLT3-ITD mutations. It will also enroll patients with relapsed/refractory high-risk myelodysplasia (MDS), where VISTA expression has been associated with low response rates. This filing advances our development in a setting of significant unmet medical need.
0 · Reply
AdityaP
AdityaP Jun. 29 at 3:31 PM
$HURA ESMO
0 · Reply
StocksandRealEstate
StocksandRealEstate Jun. 29 at 12:43 PM
$HURA cmon you dirty dog
0 · Reply
AnalyticaInvestor
AnalyticaInvestor Jun. 29 at 10:15 AM
$FBIZ Good morning, investors. Agricultural and food producers continue benefiting from structural demand and government support, while miners remain in focus as investors position around critical commodity supply chains. On the watchlist, $FBIZ continues trading near 52 week highs with strong insider alignment and solid YTD performance. Among gainers, $LVWR jumped 37%, while $PYXS and $DOMO also posted strong advances. On the downside, $HURA fell 17% despite no clear company specific catalyst. Read the full Analytica Alpha 👇 https://analyticainvestor.beehiiv.com/p/biotech-miners-lead-move
0 · Reply